Abstract 504P
Background
Evidence on the role of induction systemic therapy is limited for stage III NSCLC patients who cannot undergo upfront local therapy due to locally extensive disease or baseline poor lung function.
Methods
We analyzed 81 patients with Stage III Non-Oncogene driven NSCLC deemed ineligible for upfront local therapy by Thoracic MDT between September 2015 and January 2023, retrospectively. Of those, 44 patients received a combination of induction chemotherapy (IC) with low-dose immunotherapy (Nivolumab-42; Pembrolizumab-2) as concurrent or maintenance or both (NACT+I/O group) and 37 patients received only IC (NACT-only group) followed by assessment for local therapy. IC was platinum doublet in both groups, median number of cycles was four. Immunotherapy was given as induction only (n=26), maintenance only (n=7) or both (n=11) based on physician preference and practical feasibility. For Nivolumab, 24 patients received >0.6mg/kg q2weekly whereas 18 received <0.6mg/kg q2weekly dose. Outcomes analyzed were proportion of patients undergoing local therapy, median PFS, OS and toxicity data.
Results
Baseline characteristics are outlined in given table. 70% of patients underwent subsequent local therapy in both NACT+I/O and NACT-only groups. Median PFS was 27.5 months in NACT+I/O Group vs 13.7 months in NACT-only group (p=0.01). Median OS was 39.3 months in NACT+I/O Group vs 25.2 months in NACT-only group (p=0.21). Grade ≥3 toxicities observed in NACT + I/O vs NACT groups were hematological (7 vs 2), diarrhea (1 vs 1) and fatigue (1 vs 1). Table: 504P
Baseline characteristics
Parameter | NACT+I/O group (n=44) | NACT-Only group (n=37) |
Median Age (IQR) | 59 (49-65) | 61 (54-64) |
MaleFemale | 368 | 343 |
AdenocarcinomaSquamousMixed | 19205 | 11233 |
StageIIIAIIIBIIIC | 72413 | 11206 |
Local Therapy RadiotherapySurgeryNil | 26513 | 22413 |
Last follow-up No diseasePartial responseStable diseaseProgressive diseaseDead | 1241378 | 30101311 |
Conclusions
Induction systemic therapy resulted in the conversion of 70% stage III NSCLC to local therapy in our experience. The use of low-dose immunotherapy along with chemotherapy was safe and yielded a significant PFS benefit and numerically higher OS benefit. This may prove to be a cost-effective option for stage III NSCLC patients ineligible for upfront local therapy, especially in LMIC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract